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Abstract
Purpose of Review Recent findings on the critical pathogenic role of type 1 interferons (IFN-I) in HIV-1 persistence in humanized 
mice suggest that inhibiting IFN-I signaling transiently will reverse HIV-induced inflammatory diseases and rescue anti-HIV 
immunity to control HIV-1 reservoirs.
Recent Findings In both humanized mice and in monkeys, IFN-I signaling is functionally defined to play an important role in 
suppressing early HIV-1 and SIV infection. During persistent infection in humanized mice, however, IFN-I signaling is revealed 
to induce T cell depletion and impairment. Interestingly, in HIV-infected mice with effective combination antiretroviral therapy 
(cART), blocking IFN-I signaling reverses HIV-induced inflammation, rescues anti-HIV T cells, and reduces HIV-1 reservoirs. 
Summary These findings functionally define the role of IFN-I in HIV-1 reservoir persistence and suggest that blocking IFN-I 
signaling will provide a novel therapeutic strategy to (i) reverse inflammation-associated diseases in HIV patients under cART,
(ii) rescue host anti-HIV immunity, and (iii) reduce or control HIV-1 reservoirs.
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Introduction
HIV-1 persistence is associated with hyper-inflammatory ac-
tivation [1]. Despite efficient suppression of HIV-1 replication
and increased survival with highly active or combination an-
tiretroviral therapy (HAART or cART, respectively), HIV-1
rebounds in all patients post-cART cessation due to the
“cART-resistant” viral reservoir (latent or low-replicating
HIV infection) in lymphoid tissues [2, 3]. In addition, some
cART-treated patients with effective HIV-1 suppression fail to
reverse hyper-inflammatory or hyper-immune activation and
achieve full immune recovery [1]. The mechanism underlying
those “immune non-responder (INR)” patients remains un-
clear. Although type 1 interferons (IFN-I) are reduced under
ART [4], low levels of IFN-I persist and IFN-stimulated-genes
(ISGs) are still upregulated in peripheral blood cells or lym-
phoid organs [5, 6], which may contribute to increased clinical
complications and mortality in cART/HIV-1 patients [1].
Persistent hyper-inflammation has also been associated with
pathogenesis in non-human primates (NHP) with SIV infec-
tion, but the underlying cellular and molecular effectors re-
main elusive. Strong correlations have been established be-
tween persistently activated IFN signaling with HIV-1 [7] or
SIV disease progression [8, 9]. First, IFN and ISG responses
persist in HIV-1 infection and pathogenic SIV infections in
Asian macaque species, but resolve to baseline in non-
pathogenic SIV infections of African monkeys [10, 11].
Second, HIV-infected patients that do not exhibit disease de-
spite high plasma virus have paradoxically low levels of ISG
expression [12]. Therefore, there is a strong correlation be-
tween HIV-1 pathogenesis and IFN-signaling gene signature.
Due to the limitation of human studies, however, the function-
al role of IFN-I in HIV-1 is not clearly defined. To functionally
define the role of IFN-I in HIV-1 persistence and pathogene-
sis, several recent studies have been reported in HIV-1-
infected human patients, and in SIV-infected NHP models.
In earlier studies, administration of recombinant IFN-I
showed little or no beneficial effects in HIV-1 patients
[13–15]. In fact, it may have accelerated HIV-associated
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immunological diseases in those HIV-1 patients treated with
IFN-I [16–18]. Consistently, recent studies with peg-IFN in
HIV-1 patients under HAART showed unclear or minimal
effect on the persistence of HIV-1 reservoirs during HAART
[19–21], but enhanced HIV-1-associated CD4 depletion [19],
although lower HIV-1 replication was detected in the IFNα-
treated group after stopping HAART [19]. In SIV-infected
monkeys under cART, pegylated-IFN has shown no effect
on SIV replication or T cell function [22].
Several recent reports have attempted to define the role of
IFN-I signaling in SIV-infected NHP models, by modulating
IFN-I activities before and during SIV infection. Using a re-
combinant human IFN-1ant that binds IFNAR2 but not
IFNAR1 (thus antagonistic to wild type human IFN-I [23]),
blocking IFN-I signaling prior to and during acute SIV infec-
tion in monkeys elevated SIV replication and accelerated
AIDS progression, confirming an important role of IFN-I in
controlling early SIV infection [24]. In contrast, administra-
tion of IFN-α2a initially upregulated expression of antiviral
genes and prevented systemic infection. However, prolonged
IFN-α2a treatment induced IFN-I desensitization, increased
SIV infection, and accelerated disease progression. Thus, ear-
ly IFN-I signaling during acute SIV infection is critical to
suppress SIV replication, but its persistence may be detrimen-
tal and accelerate SIV disease progression. In a similar study,
an antibody (AGS-009) that neutralizes 11/13 of IFN-α sub-
types was infused 1 day prior to SIV infection. No obvious
effect on ISG expression was detected, but high-dose AGS-
009 treatment induced a slight increase in acute-phase viral
replication. Early blockade of IFN-α during acute infection,
interestingly, decreased the level of activated CD4+ and
CD8+ T cells during chronic infection phase, but accelerated
progression to AIDS [25]. This study again indicates that IFN-
I signaling during acute SIV infection plays a critical role to
modulate SIV disease progression. One caveat in this study is
that AGS-009 only neutralizes 11 of 13 IFN-α subtypes, not
other IFN-I types including two IFNα subtypes and IFNβ.
When administered during chronic SIV infection, IFN-1ant
significantly reduced expression of ISGs, but showed no signif-
icant effect on SIV replication or SIV-induced inflammatory
cytokines [26]. In ART-suppressed chronically SIV-infected an-
imals, IFN-1ant only marginally inhibited the low ISG expres-
sion, and showed no effect on SIV infection [26]. In addition,
IFN-I blockade showed no effect on T cell activation and ex-
haustion markers, or any adverse effect on the host. The conclu-
sion from this study is weakened by the fact that the recombi-
nant IFN-1ant, which binds IFNAR2 but not IFNAR1, still has
some low IFN-I activity to induce antiviral ISGs in human cells,
and is thus only partially antagonistic to wild type IFN-I [23].
Indeed, two doses of IFN-1ant in SIV/ART-treated animals re-
sulted in reduced expression of ISGs, but three doses showed no
such effect [26]. Its antagonistic effect is likely only obvious
when endogenous IFN-I is high, but not in SIV/ART-treated
animals with persistent but low IFN-I signaling. A more com-
plete blockade of all IFN-I signaling with IFNAR-blocking
mAb is required to clearly define the role of IFN-I signaling
during chronic SIV infection with and without ART.
Role of IFN-I Signaling in HIV-1 Infection,
Pathogenesis, and Therapy in Humanized
Mice
Humanized mice transplanted with human immune tissues or
cells have served as robust models to study HIV-1 infection
[27–29]. Humanized mice transplanted with HSC or both
HSC and thymus fragments (hu-HSC, hu-HSC/TEC [30], or
BLT [31] mice) have enabled investigation of HIV-1 persis-
tence and human immune responses to HIV-1 infection, as
well as human immunology and immunopathology [32, 33].
Humanized mice have been used to functionally define the
role of Treg [34, 35] and of plasmacytoid dendritic cell (pDC)
[36–40] in HIV immuno-pathogenesis; as well as in human
vaccine evaluation [41–43]. Importantly, HIV-1 infection re-
sults in immune activation, correlating with T cell depletion
and functional impairment in lymphoid organs of humanized
mice [40]. As in human patients, cART could efficiently in-
hibit HIV-1 replication, but HIV rebounds rapidly post-cART
discontinuation [44••, 45–47]. Furthermore, humanized mice
have been used to study HIV-1 latency [46, 47] and HIV-1
therapy by broadly neutralizing antibodies (bnAb) [48, 49],
and by IFNAR-blocking mAb [44••, 50, 51••, 52] for HIV-1
reservoir reduction or elimination. Therefore, humanized mice
are proven relevant and robust to study HIV-1 persistence,
pathogenesis, and therapy [32, 33].
Blockade of IFN-I Signaling Elevates Early HIV-1 Replication
During Acute Infection in Humanized Mice The role of pDCs
in HIV-1 disease progression is not well defined due to lack of a
robust model. We and others have reported that functional hu-
man pDCs are developed in lymphoid tissues in humanized
mouse models [29, 40]. Human pDCs are rapidly activated
by HIV-1 infection and the level of pDC activation is inversely
correlated with CD4+ T cell numbers [40], which is consistent
with the observation from HIV-1-infected patients [7] and SIV-
infected monkeys [8, 9]. To define the role of human pDCs in
HIV-1 replication and immunopathogenesis in vivo, a mono-
clonal antibody that specifically and efficiently depletes human
pDCs in all lymphoid organs in humanized mice in vivo was
developed [38, 39]. When pDCs were depleted prior to and
during early HIV-1 infection in humanized mice, no induction
of IFN-I or ISGs was detected, indicating that pDCs are the
major source of early IFN-I induction in response to HIV-1
infection. Consistently, HIV-1 replication (viremia determined
by HIV-1 genomic RNA in the blood) was elevated to 5×–10×
higher than control mice. To define the role of IFN-I in early
HIV-1 infection and pathogenesis in vivo, a monoclonal anti-
body (mAb) that blocks IFNAR1, thus all IFN-I signaling in
humanized mice, was developed. Similarly as pDC depletion,
HIV-1 replication was significantly elevated when the anti-
IFNAR1 antibody was used to completely block IFN-I signal-
ing in humanized mice [44••, 53•]. Therefore, IFN-I expression
from pDCs plays a critical role to suppress acute phase HIV-1
replication in humanized mice.
Persistent IFN-I Signaling Contributes to HIV-1 Disease and
Persistence In Vivo With depletion of pDCs during persistent
HIV-1 infection in humanized mice, HIV-1 replication was
also elevated in blood and lymphoid tissues. Consistent with
higher viral loads, human T cells expressed higher levels of
activation markers such as CD38 and HLA-DR. Surprisingly,
depletion of pDCs could rescue human immune cells from
HIV-induced depletion in the presence of increased HIV-1
replication [38, 39]. When tested with the IFNAR1-blocking
mAb during persistent HIV-1 infection, the HIV-1 replication
level in the IFNAR1-blocked group was also enhanced, asso-
ciated with complete suppression of ISG expression.
Phenocopying the pDC depletion study, human T cells were
rescued in number and functions in anti-IFNAR1mAb-treated
mice. Hence, blocking IFNAR1, like pDC depletion, also re-
verses HIV-1 disease progression during persistent HIV-1 in-
fection in humanized mice [44••, 50, 51••, 52, 53•]. Besides
human T cells, pDC depletion or IFNAR blockade also re-
versed HIV-induced immunopathology in other cell types
and organs including innate lymphoid cell type 3 (ILC3) and
hematopoietic progenitor cells (HPCs) in the bone marrow
[37, 38]. In an independent study, an IFNAR2-blocking
mAb also achieved similar ISG inhibition or rescue of human
T cells was observed in humanized mice [51••]. Distinct from
the IFNAR1-blocking mAb, however, the IFNAR2-blocking
mAb reduced HIV-1 replication in humanized mice without
ART. It is not clear if the difference on HIV-1 replication is
due to the different antibodies that target IFNAR1 or IFNAR2.
Other factors such as different HIV-1 isolates may also have
contributed to the difference. Nonetheless, these two studies
have independently concluded that persistent IFN-I signaling
during chronic HIV-1 infection contributes critically to the
depletion and impairment of human T cells in humanized
mice. This is consistent with recent findings reporting that
IFN-I plays a detrimental role during chronic LCMVinfection
and blocking IFN-I signaling by an IFNAR1 antibody could
enhance antiviral immune response and lead to early clearance
of LCMV infection [54, 55].
Blocking IFNAR in Humanized Mice with HIV-1/cART Reverses
T Cell Immune Exhaustion, Rescues Anti-HIV T Cell Activity,
and Reduces HIV-1 Reservoirs HIV-1 infection in humanized
mice can be effectively suppressed by combination ART with
two RT inhibitors and one integrase inhibitor as in human
patients. As in HIV-1 patients, cART fails to fully suppress
HIV-induced inflammation such as ISG expression. In addition,
HIV-1 reservoirs are detected by cell-associated HIV-1 DNA or
by virus outgrowth assays (VOA). When cART is stopped,
HIV-1 rebounds rapidly to pre-cART levels in all animals
[44••, 46, 47, 52]. Therefore, humanized mice provide a highly
relevant and robust model to study HIV-1 reservoir persistence,
immunopathogenesis, and therapy. In humanized mice infected
with HIV-1 and treated with cART drugs, IFNAR blockade
fully reversed inflammation, rescued human T cells, and re-
duced exhaustion markers such as PD1/TIM3 induction on
CD8 T cells. Importantly, 3 weeks of IFNAR mAb treatment
rescued anti-HIV T cell functions. Thus, effective cART led to
recovery of human Tcells but failed to reverse aberrant immune
hyper-activation and T cell exhaustion, and inhibition of IFN-I
signaling in combination with cART rescued human T cell
functions [44••, 50, 51••, 52, 53•]. Consistently, both levels of
cell-associated HIV DNA and cells with infectious HIV-1 were
reduced in mice treated with IFNAR-blocking antibodies [44••,
51••, 52]. When cARTwas stopped, a significant delay of HIV-
1 rebound was observed and the virus rebounded to a lower
level [44••]. Therefore, IFNAR blockade provides a new prom-
ising HIV-1 cure strategy to reduce or control HIV-1 reservoirs
(Fig. 1).
Conclusion and Perspectives
Recent findings in humanized mice have revealed the dual
roles of IFN-I signaling in HIV-1 infection and pathogenesis:
Fig. 1 Targeting IFN-I signaling in HIV-1 persistence, pathogenesis, and
therapy. The chronic IFN-I signaling during HIV-1 infection ± cART
contributes to HIV-1 disease progression, including hyper-immune
activation, immune impairment, and HIV-1 reservoir maintenance.
Therefore, inhibiting IFN-I signaling will likely reverse HIV/cART-
associated inflammatory diseases, rescue anti-HIV T cells, and reduce
HIV-1 reservoirs. cART, combination anti-retroviral therapy; IFNAR,
IFN-I receptor; bAb, blocking antibody. Dashed line: HIV-1 rebound
after stopping cART; red line: delayed HIV-1 rebound after immune
therapy; and blue line: stable control (functional cure) of HIV-1
rebound after immune therapy
it plays a critical role to suppress acute HIV-1 infection and to
set the anti-viral program. During chronic infection, however,
persistent IFN-I signaling contributes to HIV-associated hy-
per-inflammation, immune exhaustion, and HIV-1 persis-
tence. Intriguingly, blocking IFNAR in cART-treated human-
ized mice rescued anti-HIV immunity and reduced HIV-1 res-
ervoirs [44••, 50, 51••].
In ART-suppressed chronically SIV-infected animals, IFN-
1ant showed no effect on SIV replication or on T cell activa-
tion and exhaustion [26]. The pitfall of that study is that the
recombinant IFN-1ant, which binds IFNAR2 but not
IFNAR1, still possesses some IFN-I activity to induce antivi-
ral ISGs in human cells [23]. Its antagonistic effect is likely
only obvious when endogenous IFN-I is high, but not in SIV/
ART-treated animals with persistent but low IFN-I signaling.
A more complete blockade of IFN-I signaling with IFNAR-
blocking mAb, which blocks signaling of all type I inter-
ferons, is required to clearly define the role of IFN-I during
chronic SIV infection with and without ART.
It is important to point out the limitations of the humanized
mouse models, including limited life span, incomplete human
immune functions, and lymphoid organs. The relatively short
life span of humanized mice will prohibit prolonged HIV-1
infection and cART; thus, the model may be limited to inves-
tigation of HIV-1 reservoirs during short-term cART in vivo.
The defects in human immune functions such as lymphoid
structure and B cell IgG response, and low reconstitution in
gut-associated lymphoid tissues, should be carefully consid-
ered when interpreting experimental results for specific ques-
tions. The findings in humanized mice with IFNAR-blocking
mAb thus should be confirmed in the SIV/NHP models with
and without cART. If verified, blocking IFN-I under cART
will provide a novel strategy to treat HIV/cART-associated
inflammatory diseases in HIV-1 patients, as well as to rescue
anti-HIV T cells to control HIV-1 reservoirs (Fig. 1).
Regarding the safety of transiently blocking IFN-I signaling
in humans, clinical trials in lupus patients have shown that
treatment with an IFNAR1 antibody in healthy people for
84 days or in lupus patients for 48 weeks is clinically safe in
human subjects [56, 57].
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